Author
Bernabeu Llinares, M
Kory, J
Grogan, J
Markelc, B
Beardo, A
d'Avezac, M
Enjalbert, R
Kaeppler, J
Daly, N
Hetherington, J
Kruger, T
Maini, P
Pitt-Francis, J
Muschel, R
Alarcon, T
Byrne, H
Journal title
Proceedings of the National Academy of Sciences
DOI
10.1073/pnas.2007770117
Issue
45
Volume
117
Last updated
2024-04-09T08:59:36.18+01:00
Page
27811-27819
Abstract
Oxygen heterogeneity in solid tumors is recognized as a limiting factor for therapeutic efficacy. This heterogeneity arises from the abnormal vascular structure of the tumor, but the precise mechanisms linking abnormal structure and compromised oxygen transport are only partially understood. In this paper, we investigate the role that red blood cell (RBC) transport plays in establishing oxygen heterogeneity in tumor tissue. We focus on heterogeneity driven by network effects, which are challenging to observe experimentally due to the reduced fields of view typically considered. Motivated by our findings of abnormal vascular patterns linked to deviations from current RBC transport theory, we calculated average vessel lengths L¯¯¯ and diameters d¯ from tumor allografts of three cancer cell lines and observed a substantial reduction in the ratio λ=L¯¯¯/d¯ compared to physiological conditions. Mathematical modeling reveals that small values of the ratio λ (i.e., λ<6) can bias hematocrit distribution in tumor vascular networks and drive heterogeneous oxygenation of tumor tissue. Finally, we show an increase in the value of λ in tumor vascular networks following treatment with the antiangiogenic cancer agent DC101. Based on our findings, we propose λ as an effective way of monitoring the efficacy of antiangiogenic agents and as a proxy measure of perfusion and oxygenation in tumor tissue undergoing antiangiogenic treatment.
Symplectic ID
1130055
Favourite
Off
Publication type
Journal Article
Publication date
27 Oct 2020
Please contact us with feedback and comments about this page. Created on 03 Sep 2020 - 09:20.